Novartis pays US$678M to resolve suit over sham doctor outings
by The Associated Press
The company splurged on speaking fees, exorbitant meals, and top-shelf alcohol to get doctors to prescribe Novartis's drugs
NEW YORK — Novartis Pharmaceutical Corp. will pay $678 million to the US government and various states to settle a lawsuit over a sham speaker program that distributed cash, expensive dinners and other treats to induce doctors to prescribe its products, federal authorities announced Wednesday.
The settlement of the lawsuit was announced by Acting Manhattan US Attorney Audrey Strauss, who said the company splurged on “speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis’s drugs.”
Messages seeking comment were left with lawyers for Novartis Pharmaceuticals, which is part of Swiss drug manufacturer Novartis International AG.
The settlement resolves a 2011 whistleblower lawsuit accusing Novartis of violating the federal False Claims Act and Anti-Kickback Statute.
The company admitted giving doctors cash, golf and fishing trips, and lavish meals at some of the nation’s fanciest restaurants to induce them to prescribe Novartis cardiovascular and diabetes drugs that were reimbursed by federal healthcare programs, the government said in a release.
Federal authorities alleged that Novartis earned hundreds of millions of dollars in federal reimbursements for selling drugs sold by doctors benefiting from tens of thousands of sham educational events at high-end restaurants and other venues.
With the program, the company paid exorbitant speaker fees to doctors who gave no meaningful presentations while their guests enjoyed fine food and drinks, the government said in court papers.
In settling, Novartis made extensive factual admissions and agreed to strict limitations on any future speaker programs, according to terms of the deal.
William F. Sweeney Jr., head of New York’s FBI office, said the company’s conduct was “reprehensible and dishonest.”
“Not only did Novartis incentivize doctors to host these speaking events, reps bribed the doctors to write more prescriptions of the company’s drugs to give Novartis an advantage over competitors within their field,” he said. “Greed replaced the responsibility the public expects from those who practice medicine.”
Some high-prescribing doctors received tens or hundreds of thousands of dollars for their work as Novartis often reimbursed the same group of doctors, colleagues and friends who had dinners together repeatedly, the government said.